A delivery vehicle comprising a core (1) surrounded by a digestible polymer shell (4) having a melting and/or softening point above the body temperature of an animal or human, wherein said core comprises a lipid and/or lipophilic active ingredient (2) dispersed in a continuous polymer matrix (3). The delivery vehicle can be used to release lipid and/or lipophilic active ingredients, such as pharmaceuticals, nutraceuticals, supplements, traditional/herbal medicine, or combinations thereof, after a predetermined lag time following ingestion.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising coated API. Excess coating material that is not bound to coated API may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated API and to minimize aeration of API when mixed into suspension.

An animal treat composition for the oral administration of a medication to an animal is disclosed. The animal treat composition comprises an adhesive portion core and an outer portion. The adhesive portion adheres to oral medication inserted into the adhesive core of the treat for administration of the medication to an animal.

Pharmaceutical formulations containing a serotonin reuptake inhibitor and a smooth muscle relaxant are provided for the treatment of premature ejaculation and the increase in intravaginal ejaculatory latency time. Specific formulations contain tadalafil (1-30 mg per dose) or tamsulosin (0.05-2 mg) and escitalopram (1-30 mg) in daily dose and on-demand formulations.

The present invention is related to a combination comprising a COX inhibitor, a Mg.sup.2+ source, and ascorbic acid or a stereoisomer or a pharmaceutically acceptable salt thereof, uses and pharmaceutical composition thereof.

The present disclosure provides a hydrogel tablet for relieving alcoholism and protecting the liver as well as the preparation process and application thereof. The present disclosure firstly provides a composition with the effects of relieving alcoholism and protecting the liver, which comprises the following components on the basis of weight parts: 20˜40 parts of chitosan, 25˜55 parts of sodium alginate, 3˜20 parts of gelatin, 1˜10 parts of calcium carbonate and 0.05˜0.5 parts of gallic acid. Based on this composition, the present disclosure further provides a hydrogel tablet for relieving alcoholism and protecting the liver. In the present disclosure, chitosan, sodium alginate and calcium carbonate are compounded at an appropriate proportion to form powder particles of chitosan/sodium alginate (shell)-calcium carbonate (core), into which are additionally added gelatin and gallic acid to get a product that is the hydrogel tablet.

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10.sup.−4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.

Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).